Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Neurodegenerative Disease Market Size Changed, over the years?#_x000D_

The market size for neurodegenerative diseases has seen substantial growth in the last few years. Its value is expected to escalate from $52.3 billion in 2024 to $57.23 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this expansion during the historical period include enhanced diagnostic abilities, heightened demand for treatments addressing symptoms, an increase in clinical research activities, the augmentation of public-private collaborations, and a growing load of unfulfilled medical necessities._x000D_

_x000D_

#How Much Will the Neurodegenerative Disease Market Be Worth in 2029?#_x000D_

Anticipated robust growth is foreseen for the neurodegenerative disease market in the coming years, with the market predicted to swell to $81.23 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.2%. This expected ascent can be credited to a number of factors such as the progressive advancements in gene and cell therapy, the rising integration of digital biomarkers, the prevalence of precision medicine methodologies, an expanding repertoire of disease-modifying medications, and a heightened engagement with artificial intelligence within the realm of neurology. Throughout this period, notable trends are set to include progress in neuroimaging techniques, sophisticated drug delivery systems catering to brain targeting, the establishment of custom-tailored treatment plans, ground-breaking efforts in biomarker identification, and strides in gene editing technology._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp_x000D_

_x000D_

#Which is the Largest Company in the Neurodegenerative Disease Market?#_x000D_

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc._x000D_

_x000D_

#What Are the Main Market Drivers in the Neurodegenerative Disease Industry?#_x000D_

The surge in research and clinical studies is anticipated to push forward the growth of the neurodegenerative disease market. Clinical studies involve research conducted on human subjects to gauge the safety, effectiveness, and potential side effects of newly developed treatments, drugs, or medical devices. The surge is largely attributed to the growing demand for innovative treatments to meet changing healthcare requirements and enhance patient results. These trials assist neurodegenerative disease research by providing essential data regarding the safety and efficiency of new treatments, thereby contributing to the progress of therapeutic development and improved patient outcomes. For example, a report by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, stated in November 2023 that the total number of annual industry clinical trials begun in the UK saw a slight increase of 4.3%, escalating from 394 trials in 2021 to 411 in 2022. Hence, the upsurge in research and clinical studies is projected to boost the expansion of the neurodegenerative disease market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=24618&type=smp_x000D_

_x000D_

#How Is the Neurodegenerative Disease Market Segments Structured?#_x000D_

The neurodegenerative disease market covered in this report is segmented –_x000D_

_x000D_

1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis_x000D_

2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types_x000D_

3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration_x000D_

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels_x000D_

5) By End-User: Hospital, Retail, Online_x000D_

_x000D_

Subsegment:_x000D_

_x000D_

1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism_x000D_

2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype_x000D_

3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)_x000D_

4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease_x000D_

5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)_x000D_

_x000D_

#What Strategic Trends Are Transforming the Neurodegenerative Disease Market?#_x000D_

The primary corporations within the neurodegenerative disease market are embracing the burgeoning trend of creating novel products such as the next-generation adaptive Deep Brain Stimulation (aDBS) systems. This focus on innovation paves the way for greater accuracy in treatment, amplified impact on disease modification, and enhancement in patients’ quality of life. The next generation aDBS systems are sophisticated neurostimulation tools tailored to deliver real-time, personalized remedies pertinent to Parkinson’s disease. They dynamically adapt stimulation parameters hinged on neural reactions, achieving optimal therapeutic results and reducing potential side effects for elevated patient well-being. An illustration of such breakthrough came in February 2025 when Medtronic, a medical technology firm based in the U.S., gained U.S. Food and Drug Administration’s approval for the world’s inaugural adaptive deep brain stimulation (aDBS) system for Parkinson’s disease. The approval relates to the Percept RC neurostimulator equipped with BrainSense technology that allowed for automatic adjustments of therapy depending on a patient’s brain signals. The system offers clinically-verified symptomatic relief for patients with advanced Parkinson’s, demonstrating a significant progress in the realm of personalized neuromodulation therapies._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report_x000D_

_x000D_

#Which Global Regions Offer the Highest Growth in the Neurodegenerative Disease Market?#_x000D_

North America was the largest region in the neurodegenerative disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24618_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the neurodegenerative disease market, and how is it changing globally?_x000D_

2. Who are the major companies in the neurodegenerative disease market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the neurodegenerative disease market right now?_x000D_

4. Which products or customer segments are growing the most in the neurodegenerative disease market?_x000D_

5. What factors are helping or slowing down the growth of the neurodegenerative disease market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model